|Acarix AB, of Malmö, Sweden||CADscor system||Records the heart sounds to analyze the myocardial movement and blood flow in the coronary arteries; results are shown as a calculated coronary artery disease (CAD)-score from 0-99, categorizing patients into 3 risk groups||Detects heart sound abnormalities, such as coronary murmurs correlated to coronary stenosis and stiffness||Study compared 2 patient sets, 1,030 patients from Germany and Austria (real world) and 1,501 from the DanNICAD-1 trial in Denmark (clinical); use of CADscor in the real world demonstrated that neither patient demographics nor test results differ relevantly from the trial setting|
|Agendia Inc., of Irvine, Calif.||Mammaprint and Blueprint||70-gene breast cancer recurrence assay and 80-gene molecular subtyping assay||Provides comprehensive genomic profiling in breast cancer patients||Reported a >96% concordance when comparing Mammaprint and Blueprint results from original microarray technology to next-generation sequencing using targeted RNA-sequencing; demonstrated a 99% success rate when testing on both platforms|
|Dermtech Inc., of La Jolla, Calif.||PLAplus||Improved version of its Pigmented Lesion Assay (PLA) that combines RNA and DNA analyses||Detects melanoma||Presented abstract assessing use of PLAplus; by combining gene expression analyses with TERT promoter mutation analyses, the test's overall sensitivity was increased from 91% to 97%, as compared to the PLA test|
|Todos Medical Ltd., of Rehovot, Israel||Rapid SARS-CoV-2 3CL protease diagnostic assay||Measures 3CL protease activity||For the screening and diagnosis of symptomatic and asymptomatic COVID-19 carriers||Reported positive clinical proof of concept data; produced 100% sensitivity and 100% specificity in PCR-confirmed positive and negative COVID-19 patient samples|
For more information about individual companies and/or products, see Cortellis.